Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 400

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials

Open access
Gray, Richard, Bradley, Rosie, Braybrooke, Jeremy, Liu, Zulian, Peto, Richard, Davies, Lucy, Dodwell, David, McGale, Paul, Pan, Hongchao, Taylor, Carolyn, Barlow, William, Bliss, Judith, Bruzzi, Paolo, Cameron, David, Fountzilas, George, Loibl, Sibylle, Mackey, John, Martin, Miguel, Del Mastro, Lucia, Möbus, Volker, Nekljudova, Valentina, De Placido, Sabino, Swain, Sandra, Untch, Michael, Pritchard, Kathleen I, Bergh, Jonas, Norton, Larry, Boddington, Clare, Burrett, Julie, Clarke, Mike, Davies, Christina, Duane, Fran, Evans, Vaughan, Gettins, Lucy, Godwin, Jon, Hills, Robert, James, Sam, Liu, Hui, MacKinnon, Elizabeth, Mannu, Gurdeep, McHugh, Theresa, Morris, Philip, Read, Simon, Wang, Yaochen, Wang, Zhe, Fasching, Peter, Harbeck, Nadia, Piedbois, Pascal, Gnant, Michael, Steger, Guenther, Di Leo, Angelo, Dolci, Stella, Francis, Prue, Larsimont, Denis, Nogaret, Jean Marie, Philippson, Catherine, Piccart, Martine, Linn, Sabine, Peer, Petronella, Tjan-Heijnen, Vivianne, Vliek, Sonja, Mackey, John, Slamon, Dennis, Bartlett, John, Bramwell, Vivien H, Chen, Bingshu, Chia, Stephen, Gelmon, Karen, Goss, Paul, Levine, Mark, Parulekar, Wendy, Pater, Joseph, Rakovitch, Eileen, Shepherd, Lois, Tu, Dongsheng, Whelan, Tim, Berry, Don, Broadwater, Gloria, Cirrincione, Constance, Muss, Hyman, Weiss, Raymond, Shan, Yi, Shao, Yong Fu, Wang, Xiang, Xu, Binghe, Zhao, Dong-Bing, Bartelink, Harry, Bijker, Nina, Bogaerts, Jan, Cardoso, Fatima, Cufer, Tanja, Julien, Jean-Pierre, Poortmans, Philip, Rutgers, Emiel, van de Velde, Cornelis, Carrasco, Eva, Segui, Miguel Angel, Blohmer, Jens Uwe, Costa, Serban, Gerber, Bernd, Jackisch, Christian, von Minckwitz, Gunter, Giuliano, Mario, De Laurentiis, Michele, Bamia, Christina, Koliou, Georgia-Angeliki, Mavroudis, Dimitris, A'Hern, Roger, Ellis, Paul, Kilburn, Lucy, Morden, James, Yarnold, John, Sadoon, Mohammad, Tulusan, Augustinus H, Anderson, Stewart, Bass, Gordon, Costantino, Joe, Dignam, James, Fisher, Bernard, Geyer, Charles, Mamounas, Eleftherios P, Paik, Soon, Redmond, Carol, Wickerham, D Lawrence, Venturini, Marco, Bighin, Claudia, Pastorino, Simona, Pronzato, Paolo, Sertoli, Mario Roberto, Foukakis, Theodorus, Albain, Kathy, Arriagada, Rodrigo, Bergsten Nordström, Elizabeth, Boccardo, Francesco, Brain, Etienne, Carey, Lisa, Coates, Alan, Coleman, Robert, Correa, Candace, Cuzick, Jack, Davidson, Nancy, Dowsett, Mitch, Ewertz, Marianne, Forbes, John, Gelber, Richard, Goldhirsch, Aron, Goodwin, Pamela, Hayes, Daniel, Hill, Catherine, Ingle, James, Jagsi, Reshma, Janni, Wolfgang, Mukai, Hirofumi, Ohashi, Yasuo, Pierce, Lori, Raina, Vinod, Ravdin, Peter, Rea, Daniel, Regan, Meredith, Robertson, John, Sparano, Joseph, Tutt, Andrew, Viale, Giuseppe, Wilcken, Nicholas, Wolmark, Norman, Wood, Wiliam, Zambetti, Milvia · 2019 · The Lancet

Abstract

BACKGROUND: Increasing the dose intensity of cytotoxic therapy by shortening the intervals between cycles, or by giving individual drugs sequentially at full dose rather than in lower-dose concurrent treatment schedules, might enhance efficacy. METHODS: To clarify the relative benefits and risks of dose-intense and standard-schedule chemotherapy in early breast cancer, we did an individual patient-level meta-analysis of trials comparing 2-weekly versus standard 3-weekly schedules, and of trials comparing sequential versus concurrent administration of anthracycline and taxane chemotherapy. The primary outcomes were recurrence and breast cancer mortality. Standard intention-to-treat log-rank analyses, stratified by age, nodal status, and trial, yielded dose-intense versus standard-schedule first-event rate ratios (RRs). FINDINGS: Individual patient data were provided for 26 of 33 relevant trials identified, comprising 37 298 (93%) of 40 070 women randomised. Most women were aged younger than 70 years and had node-positive disease. Total cytotoxic drug usage was broadly comparable in the two treatment arms; colony-stimulating factor was generally used in the more dose-intense arm. Combining data from all 26 trials, fewer breast cancer recurrences were seen with dose-intense than with standard-schedule chemotherapy (10-year recurrence risk 28·0% vs 31·4%; RR 0·86, 95% CI 0·82-0·89; p<0·0001). 10-year breast cancer mortality was similarly reduced (18·9% vs 21·3%; RR 0·87, 95% CI 0·83-0·92; p<0·0001), as was all-cause mortality (22·1% vs 24·8%; RR 0·87, 95% CI 0·83-0·91; p<0·0001). Death without recurrence was, if anything, lower with dose-intense than with standard-schedule chemotherapy (10-year risk 4·1% vs 4·6%; RR 0·88, 95% CI 0·78-0·99; p=0·034). Recurrence reductions were similar in the seven trials (n=10 004) that compared 2-weekly chemotherapy with the same chemotherapy given 3-weekly (10-year risk 24·0% vs 28·3%; RR 0·83, 95% CI 0·76-0·91; p<0·0001), in the six trials (n=11 028) of sequential versus concurrent anthracycline plus taxane chemotherapy (28·1% vs 31·3%; RR 0·87, 95% CI 0·80-0·94; p=0·0006), and in the six trials (n=6532) testing both shorter intervals and sequential administration (30·4% vs 35·0%; RR 0·82, 95% CI 0·74-0·90; p<0·0001). The proportional reductions in recurrence with dose-intense chemotherapy were similar and highly significant (p<0·0001) in oestrogen receptor (ER)-positive and ER-negative disease and did not differ significantly by other patient or tumour characteristics. INTERPRETATION: Increasing the dose intensity of adjuvant chemotherapy by shortening the interval between treatment cycles, or by giving individual drugs sequentially rather than giving the same drugs concurrently, moderately reduces the 10-year risk of recurrence and death from breast cancer without increasing mortality from other causes. FUNDING: Cancer Research UK, Medical Research Council.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(18)33137-4

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Cited by

See all 400

Metadata

Authors
Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., Barlow, W., Bliss, J., Bruzzi, P., Cameron, D., Fountzilas, G., Loibl, S., Mackey, J., Martin, M., Del Mastro, L., Möbus, V., Nekljudova, V., De Placido, S., Swain, S., Untch, M., Pritchard, K. I., Bergh, J., Norton, L., Boddington, C., Burrett, J., Clarke, M., Davies, C., Duane, F., Evans, V., Gettins, L., Godwin, J., Hills, R., James, S., Liu, H., MacKinnon, E., Mannu, G., McHugh, T., Morris, P., Read, S., Wang, Y., Wang, Z., Fasching, P., Harbeck, N., Piedbois, P., Gnant, M., Steger, G., Di Leo, A., Dolci, S., Francis, P., Larsimont, D., Nogaret, J. M., Philippson, C., Piccart, M., Linn, S., Peer, P., Tjan-Heijnen, V., Vliek, S., Mackey, J., Slamon, D., Bartlett, J., Bramwell, V. H., Chen, B., Chia, S., Gelmon, K., Goss, P., Levine, M., Parulekar, W., Pater, J., Rakovitch, E., Shepherd, L., Tu, D., Whelan, T., Berry, D., Broadwater, G., Cirrincione, C., Muss, H., Weiss, R., Shan, Y., Shao, Y. F., Wang, X., Xu, B., Zhao, D.-B., Bartelink, H., Bijker, N., Bogaerts, J., Cardoso, F., Cufer, T., Julien, J.-P., Poortmans, P., Rutgers, E., van de Velde, C., Carrasco, E., Segui, M. A., Blohmer, J. U., Costa, S., Gerber, B., Jackisch, C., von Minckwitz, G., Giuliano, M., De Laurentiis, M., Bamia, C., Koliou, G.-A., Mavroudis, D., A'Hern, R., Ellis, P., Kilburn, L., Morden, J., Yarnold, J., Sadoon, M., Tulusan, A. H., Anderson, S., Bass, G., Costantino, J., Dignam, J., Fisher, B., Geyer, C., Mamounas, E. P., Paik, S., Redmond, C., Wickerham, D. L., Venturini, M., Bighin, C., Pastorino, S., Pronzato, P., Sertoli, M. R., Foukakis, T., Albain, K., Arriagada, R., Bergsten Nordström, E., Boccardo, F., Brain, E., Carey, L., Coates, A., Coleman, R., Correa, C., Cuzick, J., Davidson, N., Dowsett, M., Ewertz, M., Forbes, J., Gelber, R., Goldhirsch, A., Goodwin, P., Hayes, D., Hill, C., Ingle, J., Jagsi, R., Janni, W., Mukai, H., Ohashi, Y., Pierce, L., Raina, V., Ravdin, P., Rea, D., Regan, M., Robertson, J., Sparano, J., Tutt, A., Viale, G., Wilcken, N., Wolmark, N., Wood, W., & Zambetti, M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-04
Volume
393
Issue
10179
Pages
1440-1452
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2913286462
Cited by
400
References
25
FWCI
6.51
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. https://app.cochat.ai/papers/10.1016/s0140-6736(18)33137-4
The paper
Gray, R., Bradley, R., Braybrooke, J., Liu, Z., Peto, R., Davies, L., Dodwell, D., McGale, P., Pan, H., Taylor, C., Barlow, W., Bliss, J., Bruzzi, P., Cameron, D., Fountzilas, G., Loibl, S., Mackey, J., Martin, M., Del Mastro, L., . . . Zambetti, M. (2019). Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. The Lancet. https://doi.org/10.1016/s0140-6736(18)33137-4

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.